By down-regulating the expression of inflammatory factor interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and cyclooxygenase (COX-2), TRX prevented the NF-kappaB and MAPK signal pathway from being activated, which inhibited the inflammatory response of advanced glycation end products (AGEs) in a mouse osteoarthritis injury model (24). This evidence concerns the gene IL6 and osteoarthritis.